Peter C. Lucas

This study shows that inhibiting MALT1 protease in glioblastoma-associated macrophages reduces immunosuppression and tumor growth by reprogramming macrophages to an M1-like phenotype.

The paper develops a novel mouse cell line model of invasive lobular breast carcinoma that recapitulates human tumor phenotype and immune microenvironment, offering a preclinical platform for therapy evaluation.

The paper identifies increased GPCR pathway activity in breast cancer ovarian metastases and links it to migration and F-actin reorganization through CaSR.

This study shows that chronic inflammation and hormonal changes in older women create a tumor-permissive environment for ER+ breast cancer by increasing local estradiol and immune dysfunction.

This study shows that ER-positive ILC xenograft models replicate metastatic patterns and endocrine response of human invasive lobular breast carcinoma.

This study identifies mDia2 as a mediator of MRTF-A-dependent breast cancer cell migration and links MRTF activity to malignancy, suggesting it as a therapeutic target.

The paper introduces a new invasive lobular carcinoma cell line, WCRC-25, and demonstrates its molecular features and therapeutic response to PI3K/AKT inhibition.

This study uses spatial molecular profiling to show that mixed invasive ductal-lobular breast cancers have distinct molecular subtypes, oncogenic signatures, and mutations in different tumor regions, leading to prognostic uncertainty and therapeutic challenges.

This study shows that CRISPRa-mediated upregulation of LAMA1 compensates for LAMA2 deficiency in MDC1A fibroblasts, reducing cell migration and related pathway activity.

This study sequenced 41 stage IV breast cancer samples using MammaSeq to identify 59 genomic alterations, including 49 SNVs and 10 CNVs, with 8 having clinical significance.